Patents by Inventor Garrett W. Rhyasen

Garrett W. Rhyasen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY
    Publication number: 20180133223
    Abstract: The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group; and (b) a BCL-2 inhibitor; wherein the compound of Formula I or pharmaceutically acceptable salt thereof and a BCL-2 inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a BCL-2 inhibitor and a pharmaceutically acceptable carrier or excipient.
    Type: Application
    Filed: November 1, 2017
    Publication date: May 17, 2018
    Inventors: Ali Fattaey, Garrett W. Rhyasen
  • Combination therapy for MDS
    Patent number: 9855273
    Abstract: Disclosed are compositions and methods for the treatment of disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The disclosed methods include administering to an individual in need of such treatment a composition that may include an IRAK1/4 inhibitor. In other aspects, the method may include administration of a BLC2 inhibitor.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: January 2, 2018
    Assignee: Children's Hospital Medical Center
    Inventors: Daniel Starczynowski, Garrett W. Rhyasen
  • COMBINATION THERAPY FOR MDS
    Publication number: 20170087162
    Abstract: Disclosed are compositions and methods for the treatment of disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The disclosed methods include administering to an individual in need of such treatment a composition that may include an IRAK1/4 inhibitor. In other aspects, the method may include administration of a BLC2 inhibitor.
    Type: Application
    Filed: October 7, 2016
    Publication date: March 30, 2017
    Inventors: Daniel Starczynowski, Garrett W. Rhyasen
  • Combination therapy for MDS
    Patent number: 9504706
    Abstract: Disclosed are compositions and methods for the treatment of disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The disclosed methods include administering to an individual in need of such treatment a composition that may include an IRAK1/4 inhibitor. In other aspects, the method may include administration of a BLC2 inhibitor.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: November 29, 2016
    Assignee: Children's Hospital Medical Center
    Inventors: Daniel Starczynowski, Garrett W. Rhyasen
  • COMBINATION THERAPY FOR MDS
    Publication number: 20160038529
    Abstract: Disclosed are compositions and methods for the treatment of disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The disclosed methods include administering to an individual in need of such treatment a composition that may include an IRAK1/4 inhibitor. In other aspects, the method may include administration of a BLC2 inhibitor.
    Type: Application
    Filed: September 1, 2015
    Publication date: February 11, 2016
    Inventors: Daniel Starczynowski, Garrett W. Rhyasen
  • Combination therapy for MDS
    Patent number: 9168257
    Abstract: Disclosed are compositions and methods for the treatment of disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The disclosed methods include administering to an individual in need of such treatment a composition that may include an IRAK1/4 inhibitor. In other aspects, the method may include administration of a BLC2 inhibitor.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: October 27, 2015
    Assignee: Children's Hospital Medical Center
    Inventors: Daniel Starczynowski, Garrett W. Rhyasen
  • Combination Therapy for MDS
    Publication number: 20140350070
    Abstract: Disclosed are compositions and methods for the treatment of disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The disclosed methods include administering to an individual in need of such treatment a composition that may include an IRAK1/4 inhibitor. In other aspects, the method may include administration of a BLC2 inhibitor.
    Type: Application
    Filed: May 22, 2014
    Publication date: November 27, 2014
    Inventors: Daniel Starczynowski, Garrett W. Rhyasen